武田制药(TAK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TAK 武田制药

交易中 07-21 13:00:23 EDT

17.14

+0.09

+0.50%

最高17.25	最低17.03	成交量267.31万
今开17.17	昨收17.05	日振幅1.32%
总市值545.33亿	流通市值529.81亿	总股本31.83亿
成交额4,591万	换手率0.09%	流通股本30.92亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TAK","market":"US","secType":"STK","nameCN":"武田制药","latestPrice":17.135,"timestamp":1784653218894,"preClose":17.05,"halted":0,"volume":2673050,"delay":0,"changeRate":0.004985337243401809,"floatShares":3092000000,"shares":3182533200,"eps":-0.304241,"marketStatus":"交易中","change":0.085,"latestTime":"07-21 13:00:23 EDT","open":17.17,"high":17.25,"low":17.025,"amount":45909203.38895,"amplitude":0.013196,"askPrice":17.14,"askSize":864,"bidPrice":17.13,"bidSize":1386,"shortable":3,"etf":0,"ttmEps":-0.304241,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1784664000000},"marketStatusCode":2,"adr":0,"adrRate":0.5,"listingDate":1545627600000,"exchange":"NYSE","adjPreClose":17.05,"dividendRate":0.036102,"preHourTrading":{"tag":"盘前","latestPrice":17.14,"preClose":17.05,"latestTime":"09:29 EDT","volume":100163,"amount":1721524.618653,"timestamp":1784640599079,"change":0.09,"changeRate":0.005279,"amplitude":0.015249},"postHourTrading":{"tag":"盘后","latestPrice":17.05,"preClose":17.05,"latestTime":"19:51 EDT","volume":50695,"amount":864366.2114,"timestamp":1784591462015,"change":0,"changeRate":0,"amplitude":0.002721},"volumeRatio":0.976745,"impliedVol":0.4184,"impliedVolPercentile":0.8725},"requestUrl":"/m/hq/s/TAK/wiki","defaultTab":"wiki","newsList":[{"id":"2653277206","title":"武田制药Zasocitinib3期银屑病研究成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2653277206","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653277206?lang=zh_cn&edition=full","pubTime":"2026-07-21 20:36","pubTimestamp":1784637369,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["TAK","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652627552","title":"武田制药旗下登革热疫苗QDENGA成为首款在印度获批的登革热疫苗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2652627552","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652627552?lang=zh_cn&edition=full","pubTime":"2026-07-20 13:44","pubTimestamp":1784526271,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["TAK","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648578336","title":"武田制药股价最新上涨2.2%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2648578336","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648578336?lang=zh_cn&edition=full","pubTime":"2026-07-02 09:25","pubTimestamp":1782955520,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["TAK","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648578371","title":"英硅智能一度升逾6%，与武田制药达成超6亿美元战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2648578371","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648578371?lang=zh_cn&edition=full","pubTime":"2026-07-02 09:25","pubTimestamp":1782955508,"startTime":"0","endTime":"0","summary":"消息面上，7月2日，英硅智能宣布，已与$武田制药$达成全球战略合作协议，双方将依托 Pharma.AI 平台，在武田制药选定的多个治疗领域共同推进创新候选药物研发。根据协议，英硅智能将获得约6000万美元的项目启动费和近期里程碑付款；此外，还有资格获得基于临床前、临床、商业化及销售进展的里程碑付款，总金额最高可达约6亿美元；以及产品商业化后基于未来净销售额的分级特许权使用费。","market":"hk","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462123.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["TAK","03696","BK4585","BK4588","VXUS","BK4007","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648152080","title":"英硅智能(03696)与武田制药达成一项战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2648152080","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648152080?lang=zh_cn&edition=full","pubTime":"2026-07-02 08:47","pubTimestamp":1782953250,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英硅智能 发布公告，本集团已与武田制药达成一项战略合作协议，依托英硅智能自主研发的端到端Pharma.AI平台，在武田制药选定的疾病治疗领域共同推进候选药物研发，旨在针对具备高潜力的治疗靶点，发现具有临床差异化优势的候选药物(该合作)。武田制药将获得此次合作筛选出的新型疗法在全球范围内的独家开发、生产和商业化权利。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462094.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","03696","BK1141","TAK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648952295","title":"武田制药与英硅智能达成AI药物发现合作，价值最高达6亿美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2648952295","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648952295?lang=zh_cn&edition=full","pubTime":"2026-07-02 07:31","pubTimestamp":1782948678,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ARTY","TAK","AIPO","AGIX","BK4007","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646787475","title":"武田制药(TAK.US)首位女掌门亮相：计划三年内恢复增长，未来12个月推出三款重磅新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2646787475","media":"智通财经","labels":["executive","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646787475?lang=zh_cn&edition=full","pubTime":"2026-06-25 18:50","pubTimestamp":1782384623,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，武田制药新任首席执行官Julie Kim表示，随着公司准备推出一系列新产品，将在两到三年内恢复增长。武田制药计划在未来12个月内推出三款重磅产品，包括治疗嗜睡症的药物Oveporexton和治疗银屑病的药物Zasocitinib，同时推进另外五款处于后期研发阶段的候选药物。Kim是这家拥有245年历史的日本制药公司的首位女性领导人，也是该国企业高层中少有的外国人。Kim表示，她计划任期也同样长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458850.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"武田制药(TAK.US)首位女掌门亮相：计划三年内恢复增长，未来12个月推出三款重磅新药","news_tag":"executive,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","TAK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635761092","title":"武田制药大裁员","url":"https://stock-news.laohu8.com/highlight/detail?id=2635761092","media":"第一财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635761092?lang=zh_cn&edition=full","pubTime":"2026-05-14 11:47","pubTimestamp":1778730426,"startTime":"0","endTime":"0","summary":"5月13日，武田制药发布财报，公司计划在2026财年裁员约4500人，作为企业重组的一部分，以集中职能并降低成本。这一裁员比例接近总员工数量的10%。武田制药称，裁员后预计会有2200个空缺职位，将继续招聘。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605143737192045.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605143737192045.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["TAK","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168651479","title":"财报前瞻｜武田制药本季度营收预计增6.75%，重组费用扰动利润","url":"https://stock-news.laohu8.com/highlight/detail?id=1168651479","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168651479?lang=zh_cn&edition=full","pubTime":"2026-05-06 08:28","pubTimestamp":1778027281,"startTime":"0","endTime":"0","summary":"武田制药将于2026年05月13日盘前发布财报，市场关注收入与利润在重组费用、管线投入与产品生命周期影响下的权衡。市场一致预期本季度公司收入为11255.31亿日元，同比增长6.75%，EBIT为92.70亿日元，同比增长111.88%，每股收益为60.94日元，同比持平；关于本季度的毛利率与净利润或净利率一致预期未披露。本季度一致预期收入端增长6.75%，若消化业务维持稳定放量或结构性提价，其对毛利率的支撑将更为关键。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜武田制药本季度营收预计增6.75%，重组费用扰动利润","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TAK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622785300","title":"武田制药(TAK.US)拟计提1500亿日元重组费用，以AI驱动降本增效","url":"https://stock-news.laohu8.com/highlight/detail?id=2622785300","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622785300?lang=zh_cn&edition=full","pubTime":"2026-03-25 19:31","pubTimestamp":1774438281,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，日本制药巨头武田制药计划在即将于下月开启的新财年中计提约1500亿日元的重组费用。武田制药的重组是大型制药企业拥抱人工智能这一更广泛趋势的一部分，因为不断上涨的研发成本挤压了利润空间，加剧了市场竞争。据了解，武田制药目前已与其合作伙伴及内部AI团队在银屑病等多个管线中取得初步进展，这被市场视为其从传统药企向技术驱动型生物医药公司转型的信号。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["TAK","AIPO","AGIX","BK4007","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617959547","title":"诺和诺德、武田、默克等齐换帅，中国市场进入战略新周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2617959547","media":"动脉网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617959547?lang=zh_cn&edition=full","pubTime":"2026-03-05 09:53","pubTimestamp":1772675580,"startTime":"0","endTime":"0","summary":"2026年以来，诺和诺德、武田、默克等多家跨国药企相继完成中国区“换帅”。费森尤斯卡比中国宣布张巍3月2日加入，4月3日起任总裁兼董事长，她拥有超二十年医药行业经验；罗杰仁2月1日起任默克中国总裁，1月1日起兼任默克生命科学中国负责人，在医药健康和生命科学领域经验丰富；穆安德2月1日起任默克中国医药健康业务董事总经理，他是内部提拔晋升而来；诺和诺德中国宣布周霞萍3月31日离任，蔡琰同日接任大中国区总裁，周霞萍助力公司10款新药获批上市，蔡琰是资深管理者；1月底武田制药任命刘燕为武田中国总裁，负责整体战略和业务发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305100816a6a46605&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305100816a6a46605&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BKVL7J92.USD","LU2461242641.AUD","LU1983299246.USD","LU1699723380.USD","IE00BJT1NW94.SGD","LU1571399168.USD","BK4534","LU2125154778.USD","SG9999014575.USD","LU0868494617.USD","LU1162221912.USD","LU2125154935.USD","BK4559","TAK","LU0203345920.USD","LU0265550946.USD","ASHR","SG9999015358.SGD","BK4007","IE00BLSP4452.SGD","LU1116320737.USD","LU0980610538.SGD","LU1093756325.SGD","LU1934455194.USD","LU2112291526.USD","LU0985320562.USD","LU1430594728.SGD","SG9999001176.SGD","ASHS","LU0320765646.SGD","IE00BN8TJ469.HKD","LU0868494708.USD","SG9999001440.SGD","LU1116320901.HKD","LU1585245621.USD","LU0106261372.USD","LU1934455277.USD","LU0203347892.USD","LU2361044949.HKD","LU1037948541.HKD","LU1069347547.HKD","LU0432979614.USD","LU0861579265.USD","SG9999014542.SGD","LU1066051498.USD","LU1941712264.USD","LU0965509010.AUD","BK4614","LU2360032135.SGD","LU0238689110.USD","SG9999014559.SGD","CWEB","LU1066053197.SGD","LU0965509101.SGD","LU1929549753.HKD","NVOX","LU0648001328.SGD","LU1037948897.HKD","IE00B1BXHZ80.USD","LU0122379950.USD","LU0070302665.USD","IE0002141913.USD","IE00BLSP4239.USD","LU2468319806.SGD","LU1023059063.AUD","NVOH","IE00B2B36J28.USD","MCHI","LU0154236417.USD","SG9999002224.SGD","LU0234572021.USD","IE000M9KFDE8.USD","LU0477156953.USD","LU1066051811.HKD","LU0130517989.USD","LU0963586101.USD","LU1989771016.USD","IE00BFTCPJ56.SGD","NVO","LU0208291251.USD","LU1201861249.SGD","CQQQ","LU2361045086.USD","SG9999013999.USD","BK4599","LU1974910355.USD","LU0098860793.USD","MRK","SG9999002232.USD","SG9999001176.USD","SG9999014567.USD","LU1934455863.HKD","LU1035773651.USD","IE00BJJMRZ35.SGD","BK4550","LU1291159041.SGD","BK4532","IE00B4R5TH58.HKD","LU0265550359.USD","LU1093756168.USD","SGXZ57979304.SGD","IE0009355771.USD","LU1989772840.SGD","LU0211331839.USD","LU1066051225.USD","LU1989772923.USD","LU0965509283.SGD","LU0289739699.SGD","LU0006306889.USD","LU1061106388.HKD","LU1941712348.USD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","LU1057294990.SGD","IE00BBT3K403.USD","LU0130102774.USD","BK4585","BK4533","BK4504","SG9999015341.SGD","BK4516","LU2106854487.HKD","LU2324357040.USD","LU0942090050.USD","KWEB","LU2023250843.SGD","BK4588","LU0266013472.USD","DRAG","LU2089984988.USD","LU1917777945.USD","LU0058720904.USD","LU2361044865.SGD","LU0965508806.USD","LU0320765489.SGD","LU2023250504.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610653473","title":"武田制药以17亿美元收购Iambic 加码人工智能药物研发布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2610653473","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610653473?lang=zh_cn&edition=full","pubTime":"2026-02-09 21:26","pubTimestamp":1770643560,"startTime":"0","endTime":"0","summary":"私人控股企业Iambic于本周一宣布，已与日本武田制药达成价值超17亿美元的多年期合作，双方将借助人工智能技术，助力研发针对癌症和胃肠道疾病的小分子药物。　　根据协议内容，Iambic将获得首付款，同时还可在药物研发及商业化的各里程碑节点获得超17亿美元的相关款项，此外还能享有药品销售的特许权使用费。　　这笔合作是武田制药继去年与Nabla Bio达成聚焦蛋白类药物的同类合作后，在研发全流程布局人工智能技术的又一重要举措。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-09/doc-inhmfuky5165106.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["161631","TAK","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607061263","title":"武田制药任命刘燕为武田中国总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2607061263","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607061263?lang=zh_cn&edition=full","pubTime":"2026-01-30 10:56","pubTimestamp":1769741778,"startTime":"0","endTime":"0","summary":"南方财经1月30日电，据“武田中国”微信公众号消息，日前，武田制药宣布任命刘燕为武田中国总裁，全面负责武田中国（包括香港、澳门地区）的整体战略和业务发展。她也同时成为新成立的武田制药国际事业部管理委员会成员。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601303636687966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","TAK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605842904","title":"武田(TAK.US)1类新药奥博雷通片拟纳入优先审评 适用于1型发作性睡病患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2605842904","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605842904?lang=zh_cn&edition=full","pubTime":"2026-01-23 14:43","pubTimestamp":1769150602,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国国家药监局药品审评中心官网近日公示显示，武田申报的1类新药奥博雷通片的上市申请拟纳入优先审评，适用于治疗16岁及以上1型发作性睡病患者。发作性睡病I型是一种罕见的慢性中枢神经系统疾病，由于患者的食欲素神经元大量缺失，导致大脑和脑脊液中食欲素神经肽水平低下。2025年7月，武田宣布奥博雷通片的两项针对NT1的3期研究达到所有主要和次要终点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396593.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["TAK","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509264672","title":"日本制药股走高，中外制药涨超4%，盐野义制药涨超3%，武田制药、日本新药涨超1%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509264672","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509264672?lang=zh_cn&edition=full","pubTime":"2025-02-06 08:57","pubTimestamp":1738803431,"startTime":"0","endTime":"0","summary":"日本制药股走高，中外制药涨超4%，盐野义制药涨超3%，武田制药、日本新药涨超1%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/06085747977826.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01477","BK1574","BK1191","TAK","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507629998","title":"Julie Kim将于明年接替卫博科出任武田制药总裁兼CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2507629998","media":"港股那点事","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507629998?lang=zh_cn&edition=full","pubTime":"2025-01-30 21:58","pubTimestamp":1738245480,"startTime":"0","endTime":"0","summary":"格隆汇1月30日｜武田制药宣布，董事会一致决定由公司美国业务部总裁Julie Kim接替卫博科（Christophe Weber）出任公司总裁、CEO兼代表董事，2026年6月生效，后者届时将退休。               \n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2025-01-30/doc-inehunpu2484439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["TAK","BK4007","BRCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507669648","title":"Takeda Pharmaceutical(TAK.US)：2024年Q3财报实现营收75.13亿美元，前值为78.85亿美元；每股收益为0.44美元，前值为0.51美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507669648","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507669648?lang=zh_cn&edition=full","pubTime":"2025-01-30 17:24","pubTimestamp":1738229099,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical(TAK.US)：2024年Q3财报实现营收75.13亿美元，前值为78.85亿美元；每股收益为0.44美元，前值为0.51美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/30172447906893.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["TAK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188918826","title":"武田药品提高2024财年指导预期：核心收入和利润预期小幅增长，核心每股收益调整为持平或略有下降，自由现金流提高至5500亿至6500亿日元","url":"https://stock-news.laohu8.com/highlight/detail?id=1188918826","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188918826?lang=zh_cn&edition=full","pubTime":"2025-01-30 15:30","pubTimestamp":1738222214,"startTime":"0","endTime":"0","summary":"武田药品更新了其2024财年的管理指导和报告及核心预测。这些调整主要受产品动能和运营费用节约的推动，同时也反映了修订后的全年汇率假设。根据最新的预测，核心收入预计将小幅增长，而核心每股收益预计与之前持平或略微下降。此外，自由现金流的预期被上调至5500亿至6500亿日元。查看更多详情，请参考《2024财年财务预测修订公告》。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TAK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118495484","title":"武田药品2024年第三季度GAAP每股收益为15.01日元，同比下降67.38日元，销售额为1.144万亿日元，超出预期1.139万亿日元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118495484","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118495484?lang=zh_cn&edition=full","pubTime":"2025-01-30 14:56","pubTimestamp":1738220174,"startTime":"0","endTime":"0","summary":"武田药品  报告季度每股收益为15.01日元。这较去年同期的每股收益67.38日元下降了77.72%。公司报告季度销售额为1.144万亿日元，超出分析师一致预期的1.139万亿日元，超出0.42%。以上内容来自Benzinga Earnings专栏，原文如下：Takeda Pharmaceutical  reported quarterly earnings of 15.01 per share. This is a 77.72 percent decrease over earnings of 67.38 per share from the same period last year. The company reported quarterly sales of 1.144 trillion which beat the analyst consensus estimate of 1.139 trillion by 0.42 percent. This is a 2.97 percent increase over sales of 1.111 trillion the same","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"武田药品2024年第三季度GAAP每股收益为15.01日元，同比下降67.38日元，销售额为1.144万亿日元，超出预期1.139万亿日元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TAK"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.takeda.com","stockEarnings":[{"period":"1week","weight":0.034},{"period":"1month","weight":0.0909},{"period":"3month","weight":-0.0006},{"period":"6month","weight":0.0603},{"period":"1year","weight":0.1816},{"period":"ytd","weight":0.0936}],"compareEarnings":[{"period":"1week","weight":-0.0095},{"period":"1month","weight":-0.0062},{"period":"3month","weight":0.054},{"period":"6month","weight":0.0827},{"period":"1year","weight":0.1825},{"period":"ytd","weight":0.0882}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Takeda Pharmaceutical Company Limited是一家在日本注册成立的上市公司成立于1925年1月12日。该公司是一家全球研发驱动的生物制药公司，专注于胃肠道与炎症、神经科学、肿瘤学以及血浆疗法和疫苗领域的治疗药物开发。其商业努力集中在关键业务领域，研发引擎聚焦于三大核心治疗领域，利用内部研究和外部合作伙伴。公司致力于将科学转化为创新药物，并通过数字化和先进技术提高运营效率。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.042998},{"month":2,"riseRate":0.5,"avgChangeRate":0.004795},{"month":3,"riseRate":0.5,"avgChangeRate":-0.003367},{"month":4,"riseRate":0.5,"avgChangeRate":-0.0142},{"month":5,"riseRate":0.375,"avgChangeRate":-0.006879},{"month":6,"riseRate":0.375,"avgChangeRate":-0.010539},{"month":7,"riseRate":0.5,"avgChangeRate":0.003185},{"month":8,"riseRate":0.714286,"avgChangeRate":0.014511},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.022057},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.062844},{"month":11,"riseRate":0.714286,"avgChangeRate":0.063577},{"month":12,"riseRate":0.714286,"avgChangeRate":0.019204}],"exchange":"NYSE","name":"武田制药","nameEN":"Takeda Pharmaceutical Co Ltd"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"武田制药(TAK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供武田制药(TAK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"武田制药,TAK,武田制药股票,武田制药股票老虎,武田制药股票老虎国际,武田制药行情,武田制药股票行情,武田制药股价,武田制药股市,武田制药股票价格,武田制药股票交易,武田制药股票购买,武田制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"武田制药(TAK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供武田制药(TAK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}